<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03396341</url>
  </required_header>
  <id_info>
    <org_study_id>17-489</org_study_id>
    <nct_id>NCT03396341</nct_id>
  </id_info>
  <brief_title>Responses to Genetic Risk Modifier Testing Among Women With BRCA1/2 Mutations</brief_title>
  <official_title>Responses to Genetic Risk Modifier Testing Among Women With BRCA1/2 Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Phenogen Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe how women with BRCA1/2 mutations react to genetic
      risk modifier testing, and to examine how they make decisions about their healthcare.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2018</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients that opt for preventive mastectomy or to pursue surveillance</measure>
    <time_frame>3 years</time_frame>
    <description>Hierarchical level modeling (HLM) will be implemented to assess the effect of genetic risk modifier testing on Decisional Conflict Scale score (DCS), allowing for baseline effects via a random intercept.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Genetic Testing</condition>
  <condition>BRCA1/2</condition>
  <arm_group>
    <arm_group_label>patients receiving a positive BRCA1/2 mutation result</arm_group_label>
    <description>All interested participants will provide a saliva sample for genetic risk modifier testing, and will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Salvia sample</intervention_name>
    <description>salvia sample</description>
    <arm_group_label>patients receiving a positive BRCA1/2 mutation result</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Participants will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system</description>
    <arm_group_label>patients receiving a positive BRCA1/2 mutation result</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      saliva sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Potential participants (i.e., patients receiving a positive BRCA1/2 mutation result) will
        be identified and approached by their primary genetic counselor.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female MSK patient, age 25 years or older (given that women under this age are not
             generally recommended to receive BRCA1/2 genetic testing)

          -  Completed full sequence BRCA1/2 genetic testing with a deleterious BRCA1/2 mutation
             identified

          -  No personal history of breast cancer

          -  English-fluent; the surveys were designed and validated in English and are not
             currently available in other languages. Translation of questionnaires into other
             languages would require reestablishing the reliability and validity of these measures.
             Therefore, participants must be able to communicate in English to complete the
             surveys.

        Exclusion Criteria:

          -  Previous receipt of any prophylactic mastectomy.

          -  Major psychiatric illness or cognitive impairment that in the judgment of the study
             investigators or study staff would preclude study participation.

          -  Any patients who are unable to comply with the study procedures as determined by the
             study investigators or study staff.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>BRACA 1/2 mutation carriers</gender_description>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jada Hamilton, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jada Hamilton, PhD, MPH</last_name>
    <phone>646-888-0049</phone>
    <email>hamiltoj@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Robson, MD</last_name>
    <phone>646-888-5486</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering at Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jada Hamilton, PhD, MPH</last_name>
      <phone>646-888-0049</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jada Hamilton, PhD, MPH</last_name>
      <phone>646-888-0049</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jada Hamilton, PhD, MPH</last_name>
      <phone>646-888-0049</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jada Hamilton, PhD, MPH</last_name>
      <phone>646-888-0049</phone>
    </contact>
    <contact_backup>
      <last_name>Mark Robson, MD</last_name>
      <phone>646-888-5486</phone>
    </contact_backup>
    <investigator>
      <last_name>Jada Hamilton, PhD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Rockville Centre</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jada Hamilton, PhD, MPH</last_name>
      <phone>646-888-0049</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2018</study_first_submitted>
  <study_first_submitted_qc>January 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2018</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BRCA1/2 Mutations</keyword>
  <keyword>17-489</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

